U.S. FDA Staff Question Study on Recordati S.p.A Blood Drug

Reuters -- U.S. health regulators questioned a study by Recordati SpA (RECI.MI), casting doubt on the ability of the company's proposed drug to treat elevated levels of ammonia in the blood.